RxDoctor Payments Data

William Timm, MD

Infectious Disease · Brookfield, WINPI 1902856016

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $2,700 of the $3,648 with a category attached, or 74.0%. AbbVie accounts for 87.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $2,841 and has fallen 91.3% since, to $246 in 2025. Among infectious disease clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,648in general payments, 2019–2025

Across 49 payments — averaging $74.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Insmed, Inc.$245
  • Janssen Products, LP$100
  • Astellas Pharma US Inc$33
  • Gilead$28
  • Pfizer$23
  • plus $13 from 1 others

What the payments were for

  • Speaking & faculty fees$2,70074%
  • Food & beverage$68819%
  • Education$2607%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)37$3,206
Insmed, Inc.7$245
Janssen Products, LP1$100
Astellas Pharma US Inc1$33
Gilead1$28
Pfizer1$23
Shionogi Inc1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,648 in reported general payments places this provider in the 90th percentile of 133 infectious disease providers in Wisconsin.

See all infectious disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$161,324
Medicare patients
248
Services billed
19,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala54$222,292
PrezcobixDarunavir/Cobicistat13$30,606
Daptomycin70$22,423
ErtapenemErtapenem Sodium36$18,017
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam23$3,212
CefuroximeCefuroxime Axetil79$2,993
CeftriaxoneCeftriaxone Sodium101$2,679
Cefepime Hcl20$2,072
Cefadroxil30$1,224
Vancomycin Hcl21$1,156
Doxycycline Hyclate36$888
Rifampin15$864
Ethambutol Hcl14$841
Cefazolin Sodium18$723
Cephalexin47$722

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$28$222,29254 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 133 infectious disease providers in Wisconsin.

Other infectious disease in Brookfield

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →